Barriers to optimal heart failure treatment are broken down by the expert panelists.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. Despite remarkable advances, challenges remain in heart failure care. Albert identifies patient barriers such as transportation, scheduling, and medication adherence. However, the biggest issue is optimizing guideline-directed medical therapy because many providers do not maximize therapies. Desai notes that disparities in accessing new technologies could worsen without efforts to reach all patients equally. He advocates redefining the care team and delivery models. Axsom recommends managing patients remotely using home devices and data customized by insights into individuals’ lives. Wright cites overcoming outdated practices and misinformation as gaps, emphasizing education about current evidence. With more advanced practice providers, ongoing learning is essential. In summary, major needs include closing evidence-practice gaps, eliminating disparities, supporting patients holistically, and continuously updating providers on the evolving landscape.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More